title: Care of patients with hepatitis C and HIV co-infection.
authors.forename: Vincent
authors.initials: V
authors.lastname: Soriano
authors.forename: Massimo
authors.initials: M
authors.lastname: Puoti
authors.forename: Mark
authors.initials: M
authors.lastname: Sulkowski
authors.forename: Stefan
authors.initials: S
authors.lastname: Mauss
authors.forename: Patrice
authors.initials: P
authors.lastname: Cacoub
authors.forename: Antonietta
authors.initials: A
authors.lastname: Cargnel
authors.forename: Douglas
authors.initials: D
authors.lastname: Dieterich
authors.forename: Angelos
authors.initials: A
authors.lastname: Hatzakis
authors.forename: Jurgen
authors.initials: J
authors.lastname: Rockstroh
mesh_terms: D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006679:HIV Seropositivity / Q000150:complications / Q000188:drug therapy; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D016031:Liver Transplantation; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D044966:Anti-Retroviral Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a